SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021
From January 18th to August 13th, 2021, 13,804 unvaccinated and 1,156 patients who had received at least one COVID-19 vaccine dose were tested qPCR-positive for SARS-CoV-2 in our center. Among vaccinated patients, 949, 205 and 2 had received a single, two or three vaccine doses, respectively. Most patients (80.3%) had received the Pfizer-BioNTech vaccine. The SARS-CoV-2 variants infecting vaccinated patients varied over time, reflecting those circulating in the Marseille area, with a predominance of the Marseille-4/20A.EU2 variant from weeks 3 to 6, of the Alpha/20I variant from weeks 7 to 25, and of the Delta/21A variant from week 26. SARS-CoV-2 infection was significantly more likely to occur in the first 13 days post-vaccine injection in those who received a single dose (48.9%) than two doses (27.4%, p< 10–3). Among 161 patients considered as fully vaccinated, i.e., >14 days after the completion of the vaccinal scheme (one dose for Johnson and Johnson and two doses for Pfizer/BioNTech, Moderna and Sputnik vaccines), 10 (6.2%) required hospitalization and four (2.5%) died. Risks of complications increased with age in a nonlinear pattern, with a first breakpoint at 54, 33, and 53 years for death, transfer to ICU, and hospitalization, respectively. Among patients infected by the Delta/21A or Alpha/20I variants, partial or complete vaccination exhibited a protective effect with a risk divided by 3.1 for mortality in patients ≥ 55 years, by 2.8 for ICU transfer in patients ≥ 34 years, and by 1.8 for hospitalization in patients ≥ 54 years. Compared to partial vaccination, complete vaccination provided an even stronger protective effect, confirming effectiveness to prevent severe forms of COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in Microbiology - 12(2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pierre-Edouard Fournier [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.3389/fmicb.2021.796807 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ01405812X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ01405812X | ||
| 003 | DE-627 | ||
| 005 | 20230310063114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmicb.2021.796807 |2 doi | |
| 035 | |a (DE-627)DOAJ01405812X | ||
| 035 | |a (DE-599)DOAJ257152a6def24df1ad644ef87331dde2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Pierre-Edouard Fournier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a From January 18th to August 13th, 2021, 13,804 unvaccinated and 1,156 patients who had received at least one COVID-19 vaccine dose were tested qPCR-positive for SARS-CoV-2 in our center. Among vaccinated patients, 949, 205 and 2 had received a single, two or three vaccine doses, respectively. Most patients (80.3%) had received the Pfizer-BioNTech vaccine. The SARS-CoV-2 variants infecting vaccinated patients varied over time, reflecting those circulating in the Marseille area, with a predominance of the Marseille-4/20A.EU2 variant from weeks 3 to 6, of the Alpha/20I variant from weeks 7 to 25, and of the Delta/21A variant from week 26. SARS-CoV-2 infection was significantly more likely to occur in the first 13 days post-vaccine injection in those who received a single dose (48.9%) than two doses (27.4%, p< 10–3). Among 161 patients considered as fully vaccinated, i.e., >14 days after the completion of the vaccinal scheme (one dose for Johnson and Johnson and two doses for Pfizer/BioNTech, Moderna and Sputnik vaccines), 10 (6.2%) required hospitalization and four (2.5%) died. Risks of complications increased with age in a nonlinear pattern, with a first breakpoint at 54, 33, and 53 years for death, transfer to ICU, and hospitalization, respectively. Among patients infected by the Delta/21A or Alpha/20I variants, partial or complete vaccination exhibited a protective effect with a risk divided by 3.1 for mortality in patients ≥ 55 years, by 2.8 for ICU transfer in patients ≥ 34 years, and by 1.8 for hospitalization in patients ≥ 54 years. Compared to partial vaccination, complete vaccination provided an even stronger protective effect, confirming effectiveness to prevent severe forms of COVID-19. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a vaccine | |
| 650 | 4 | |a death | |
| 650 | 4 | |a intensive care | |
| 650 | 4 | |a hospitalization | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Pierre-Edouard Fournier |e verfasserin |4 aut | |
| 700 | 0 | |a Linda Houhamdi |e verfasserin |4 aut | |
| 700 | 0 | |a Philippe Colson |e verfasserin |4 aut | |
| 700 | 0 | |a Philippe Colson |e verfasserin |4 aut | |
| 700 | 0 | |a Sébastien Cortaredona |e verfasserin |4 aut | |
| 700 | 0 | |a Sébastien Cortaredona |e verfasserin |4 aut | |
| 700 | 0 | |a Lea Delorme |e verfasserin |4 aut | |
| 700 | 0 | |a Carole Cassagne |e verfasserin |4 aut | |
| 700 | 0 | |a Carole Cassagne |e verfasserin |4 aut | |
| 700 | 0 | |a Jean-Christophe Lagier |e verfasserin |4 aut | |
| 700 | 0 | |a Jean-Christophe Lagier |e verfasserin |4 aut | |
| 700 | 0 | |a Hervé Chaudet |e verfasserin |4 aut | |
| 700 | 0 | |a Hervé Chaudet |e verfasserin |4 aut | |
| 700 | 0 | |a Hervé Chaudet |e verfasserin |4 aut | |
| 700 | 0 | |a Hervé Tissot-Dupont |e verfasserin |4 aut | |
| 700 | 0 | |a Hervé Tissot-Dupont |e verfasserin |4 aut | |
| 700 | 0 | |a Audrey Giraud-Gatineau |e verfasserin |4 aut | |
| 700 | 0 | |a Audrey Giraud-Gatineau |e verfasserin |4 aut | |
| 700 | 0 | |a Florence Fenollar |e verfasserin |4 aut | |
| 700 | 0 | |a Florence Fenollar |e verfasserin |4 aut | |
| 700 | 0 | |a Matthieu Million |e verfasserin |4 aut | |
| 700 | 0 | |a Matthieu Million |e verfasserin |4 aut | |
| 700 | 0 | |a Didier Raoult |e verfasserin |4 aut | |
| 700 | 0 | |a Didier Raoult |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Microbiology |d Frontiers Media S.A., 2011 |g 12(2022) |w (DE-627)DOAJ000031836 |x 1664302X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fmicb.2021.796807 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/257152a6def24df1ad644ef87331dde2 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fmicb.2021.796807/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1664-302X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 | ||